IN2014MN01755A - - Google Patents

Info

Publication number
IN2014MN01755A
IN2014MN01755A IN1755MUN2014A IN2014MN01755A IN 2014MN01755 A IN2014MN01755 A IN 2014MN01755A IN 1755MUN2014 A IN1755MUN2014 A IN 1755MUN2014A IN 2014MN01755 A IN2014MN01755 A IN 2014MN01755A
Authority
IN
India
Prior art keywords
compounds
formula
present disclosure
heteroaryl
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01755(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN1755MUN2014 priority Critical patent/IN2014MN01755A/en
Publication of IN2014MN01755A publication Critical patent/IN2014MN01755A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IN1755MUN2014 2012-03-14 2013-03-11 IN2014MN01755A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1755MUN2014 IN2014MN01755A (fr) 2012-03-14 2013-03-11

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
IN1755MUN2014 IN2014MN01755A (fr) 2012-03-14 2013-03-11
PCT/IB2013/051908 WO2013136249A1 (fr) 2012-03-14 2013-03-11 Composés hétérocyclyle en tant qu'inhibiteurs de mek

Publications (1)

Publication Number Publication Date
IN2014MN01755A true IN2014MN01755A (fr) 2015-07-03

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1754MUN2014 IN2014MN01754A (fr) 2012-03-14 2013-03-11
IN1755MUN2014 IN2014MN01755A (fr) 2012-03-14 2013-03-11

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN1754MUN2014 IN2014MN01754A (fr) 2012-03-14 2013-03-11

Country Status (36)

Country Link
US (5) US9428499B2 (fr)
EP (2) EP2834237B1 (fr)
JP (3) JP6093384B2 (fr)
KR (4) KR20140138910A (fr)
CN (4) CN104203947A (fr)
AP (2) AP3859A (fr)
AU (4) AU2013234009B2 (fr)
BR (1) BR112014022713B1 (fr)
CA (2) CA2865167C (fr)
CL (2) CL2014002412A1 (fr)
CO (2) CO7160029A2 (fr)
CR (2) CR20140464A (fr)
CU (2) CU24335B1 (fr)
DK (2) DK2834236T3 (fr)
DO (2) DOP2014000204A (fr)
EA (2) EA028232B1 (fr)
ES (2) ES2741896T3 (fr)
GE (2) GEP201706774B (fr)
GT (2) GT201400196A (fr)
HK (2) HK1202538A1 (fr)
IL (2) IL234560A (fr)
IN (2) IN2014MN01754A (fr)
MA (2) MA37400B1 (fr)
MX (3) MX366426B (fr)
MY (2) MY175950A (fr)
NI (2) NI201400108A (fr)
NZ (2) NZ629432A (fr)
PE (2) PE20141974A1 (fr)
PH (2) PH12014502041B1 (fr)
PL (1) PL2834237T3 (fr)
SG (2) SG11201405006PA (fr)
TN (2) TN2014000356A1 (fr)
TR (1) TR201811976T4 (fr)
UA (2) UA114906C2 (fr)
WO (2) WO2013136249A1 (fr)
ZA (1) ZA201406186B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CU24335B1 (es) 2012-03-14 2018-04-03 Lupin Ltd Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
UA117347C2 (uk) 2012-06-13 2018-07-25 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105263931B (zh) 2013-04-19 2019-01-25 因赛特公司 作为fgfr抑制剂的双环杂环
WO2015058589A1 (fr) 2013-10-25 2015-04-30 上海恒瑞医药有限公司 Dérivés pyridiques de cétone, leur procédé de préparation et leur application pharmaceutique
WO2016009306A1 (fr) * 2014-07-15 2016-01-21 Lupin Limited Composés hétérocyclyles utilisés comme inhibiteurs de mek
WO2016035008A1 (fr) * 2014-09-04 2016-03-10 Lupin Limited Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AR114164A1 (es) * 2017-12-21 2020-07-29 Boehringer Ingelheim Int Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CA3129665A1 (fr) 2019-03-21 2020-09-24 Onxeo Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer
CA3142239A1 (fr) 2019-06-19 2020-12-24 Boehringer Ingelheim International Gmbh Polytherapie anticancereuse
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4003356A1 (fr) * 2019-07-30 2022-06-01 Edvince AB Inhibiteur de mek pour le traitement d'un accident vasculaire cérébral
EP3797899A1 (fr) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Dispositif et procédé de détection d'un mouvement d'un corps dans une installation industrielle
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021089791A1 (fr) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021113479A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US11945812B2 (en) 2020-06-02 2024-04-02 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
CN117479942A (zh) 2021-04-09 2024-01-30 勃林格殷格翰国际有限公司 抗癌疗法
EP4323066A1 (fr) * 2021-04-16 2024-02-21 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
CA3220274A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2023099592A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh 2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099620A1 (fr) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
IL162721A0 (en) * 2002-01-22 2005-11-20 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
PT1761528E (pt) * 2004-06-11 2008-04-15 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2010121646A1 (fr) 2009-04-21 2010-10-28 Novartis Ag Composés hétérocycliques comme inhibiteurs de mek
CU24335B1 (es) * 2012-03-14 2018-04-03 Lupin Ltd Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer

Also Published As

Publication number Publication date
US20150133424A1 (en) 2015-05-14
DOP2014000204A (es) 2015-02-15
US9555035B2 (en) 2017-01-31
CU20140110A7 (es) 2014-11-27
GT201400196A (es) 2017-09-28
JP6630771B2 (ja) 2020-01-15
EP2834237B1 (fr) 2018-06-06
US20160331753A1 (en) 2016-11-17
BR112014022713A2 (fr) 2017-06-20
PH12014502040A1 (en) 2014-11-24
MX366426B (es) 2019-07-08
CA2865167A1 (fr) 2013-09-19
DK2834236T3 (da) 2019-08-26
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
UA114907C2 (uk) 2017-08-28
CN104271577A (zh) 2015-01-07
AP3859A (en) 2016-10-31
MX355526B (es) 2018-04-20
CN104203947A (zh) 2014-12-10
CN108383836B (zh) 2021-11-12
IL234560A (en) 2017-06-29
EP2834236A1 (fr) 2015-02-11
US20170112840A1 (en) 2017-04-27
KR20190073597A (ko) 2019-06-26
WO2013136249A1 (fr) 2013-09-19
CA2865167C (fr) 2019-08-06
MA37400A1 (fr) 2016-05-31
ES2684517T3 (es) 2018-10-03
IN2014MN01754A (fr) 2015-07-03
CL2014002411A1 (es) 2015-04-06
HK1206020A1 (en) 2015-12-31
AU2017200493B2 (en) 2018-03-29
AP2014008009A0 (en) 2014-10-31
PH12014502040B1 (en) 2014-11-24
GEP201706671B (en) 2017-05-25
KR102241111B1 (ko) 2021-04-15
AU2018202568A1 (en) 2018-05-10
CA2865164C (fr) 2021-06-08
JP2018115215A (ja) 2018-07-26
AU2013234014B2 (en) 2017-02-02
MX2014010928A (es) 2015-04-10
PL2834237T3 (pl) 2018-11-30
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
GT201400195A (es) 2017-11-09
CN107698585A (zh) 2018-02-16
EP2834236B1 (fr) 2019-05-22
CR20140464A (es) 2014-11-28
EP2834237A1 (fr) 2015-02-11
MA37405A1 (fr) 2016-03-31
NZ629442A (en) 2016-12-23
KR102240101B1 (ko) 2021-04-14
CL2014002412A1 (es) 2015-03-06
AU2017200493A1 (en) 2017-02-16
UA114906C2 (uk) 2017-08-28
NZ629432A (en) 2017-01-27
IL234559A (en) 2017-06-29
ES2741896T3 (es) 2020-02-12
TN2014000357A1 (en) 2015-12-21
AU2018202568B2 (en) 2019-05-09
JP2015509975A (ja) 2015-04-02
PE20141974A1 (es) 2014-12-12
CU24335B1 (es) 2018-04-03
US20150299186A1 (en) 2015-10-22
MY174188A (en) 2020-03-12
PE20141973A1 (es) 2014-12-12
NI201400107A (es) 2014-11-26
BR112014022713B1 (pt) 2021-09-08
US9827247B2 (en) 2017-11-28
TR201811976T4 (tr) 2018-09-21
MX355474B (es) 2018-04-16
EA201491671A1 (ru) 2014-12-30
GEP201706774B (en) 2017-11-27
EA028232B1 (ru) 2017-10-31
US9428499B2 (en) 2016-08-30
DOP2014000203A (es) 2015-02-15
AP2014008008A0 (en) 2014-10-31
ZA201406186B (en) 2016-06-29
KR20140138910A (ko) 2014-12-04
MX2014010925A (es) 2015-04-10
CU24272B1 (es) 2017-08-08
PH12014502041A1 (en) 2014-11-24
US9573944B2 (en) 2017-02-21
JP2015514056A (ja) 2015-05-18
JP6431770B2 (ja) 2018-11-28
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
PH12014502041B1 (en) 2014-11-24
CR20140463A (es) 2014-11-28
HK1202538A1 (en) 2015-10-02
US9969731B2 (en) 2018-05-15
KR20190100472A (ko) 2019-08-28
CO7170131A2 (es) 2015-01-28
MA37400B1 (fr) 2019-11-29
SG11201405006PA (en) 2014-10-30
AU2013234009A1 (en) 2014-09-25
AP3834A (en) 2016-09-30
CA2865164A1 (fr) 2013-09-19
KR20140138911A (ko) 2014-12-04
CU20140109A7 (es) 2014-11-27
SG11201405007QA (en) 2014-10-30
JP6093384B2 (ja) 2017-03-08
NI201400108A (es) 2014-11-28
WO2013136254A1 (fr) 2013-09-19
DK2834237T3 (en) 2018-08-27
AU2013234009B2 (en) 2016-10-27
US20170101408A1 (en) 2017-04-13
CN108383836A (zh) 2018-08-10

Similar Documents

Publication Publication Date Title
IN2014MN01755A (fr)
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
PH12016501204A1 (en) Syk inhibitors
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
IN2014MN02598A (fr)
IN2014DN09434A (fr)
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
PH12014502524A1 (en) Carboxylic acid compounds
NZ715747A (en) Syk inhibitors
EA201591195A1 (ru) Новые хинолоновые производные
IN2015DN01119A (fr)
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201600434A1 (ru) Применение производных бензимидазолпролина
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
IN2013DN02555A (fr)
IN2015DN01329A (fr)
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao